On August 12, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.

Proceeds from the financing will support Phase 1 clinical development and generation of early proof-of-concept data for IDP-001, the company’s lead oncology program, as well as the advancement of InduPro’s broader preclinical pipeline.

The Wilson Sonsini team that advised InduPro on the transaction included Kenneth Clark, Christina Poulsen, Lowell Segal, Alex Weber, Priyanka Nawathe, Rachel Slyker, Jacob Morales, and Carolyn Walworth.

For more information, please see InduPro’s news release. Additional coverage can be found on Pulse 2.0.